Journal of Pediatric Health Care
Volume 23, Issue 4 , Pages 206-212 , July 2009

Pharmacotherapy and Surgery Treatment for the Severely Obese Adolescent

  • Teri Woo, PhD, RN, CPNP

      Affiliations

    • Corresponding Author InformationCorrespondence: Teri Woo, PhD, RN, CPNP, University of Portland School of Nursing, 5000 N Willamette Blvd, Portland, OR 92703.

References 

  1. August GP, Caprio S, Fennoi I, Freemark M, Kaufman FR, Lustig RH, et al. Prevention and treatment of pediatric obesity: An Endocrine Society clinical practice guideline based on expert opinion. Journal of Clinical Endocrinology & Metabolism. 2008;93:4575–4599
  2. Barlow SE, the Expert Committee . Expert Committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: Summary report. Pediatrics. 2007;120:S164–S192
  3. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JI. Behavior therapy and sibutramine for the treatment of adolescent obesity: A randomized controlled trial. Annals of Internal Medicine. 2003;145:80–91
  4. Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, Perry AC, et al. for the Sibutramine Adolescent Study Group Effects of sibutramine treatment in obese adolescents: A randomized trial. Annals of Internal Medicine. 2006;145:81–90
  5. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: A randomized controlled trial. Journal of the American Medical Association. 2005;293:2873–2883
  6. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. Journal of the American Medical Association. 1999;281:235–242
  7. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schacheter LM, Skinner S, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: A randomized controlled trial. Journal of the American Medical Association. 2008;299I:316–323
  8. Drugdevelopment-technology.com. (2009). Acomplia (rimonabant)—investigational agent for the management of obesity. Retrieved April 5, 2009, from http://www.drugdevelopment-technology.com/projects/rimonabant/
  9. Encinosa WE, Bernard DM, Steiner CA, Chen CC. Use and costs of bariatric surgery and prescription weight-loss medications. Health Affairs. 2005;24:1039–1046
  10. Ferchak CV, Meneghini LF. Obesity, bariatric surgery and type 2 diabetes—a systematic review. Dia-betes/Metabolism Research and Reviews. 2004;20:438–445
  11. Hansen D, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, et al. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. International Journal of Obesity and Related Metabolic Disorders. 2001;25:496–501
  12. Haynes B, Gibbs C, Gourash W, Miller R, Trout S, Walters-Salas T, et al. Adolescent weight loss surgery: Current issues. Bariatric Nursing and Surgical Patient Care. 2008;3:197–204
  13. IPEG Standards and Safety Committee . IPEG guidelines for surgical treatment of extremely obese adolescents. Journal of Laparoendoscopic & Advanced Surgical Techniques. 2008;18:xiv–xvi
  14. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group (Sibutramine Trial of Obesity Reduction and Maintenance). Lancet. 2000;356:2119–2125
  15. Levitsky LL, Misra M, Boepple PA, Hoppin AG. Adolescent obesity and bariatric surgery. Current Opinion in Endocrinology, Diabetes, and Obesity. 2009;16:37–44
  16. McGovern L, Johnson JN, Paulo R, Hettinger A, Singhal V, Kamath C, et al. Treatment of pediatric obesity. A systematic review and meta-analysis of randomized trials. Journal of Clinical Endocrinology & Metabolism. 2008;93:4600–4605
  17. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. Journal of the American Medical Association. 2006;295:1549–1555
  18. Roche Pharmaceuticals. (1999-2008). Orlistat label. Retrieved April 5, 2009, from http://www.rocheusa.com/products/xenical/pi.pdf
  19. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. British Medical Journal, (Clinical Research Ed.). 2007;335:194–199
  20. Spear BA, Barlow SE, Ervin C, Ludwig DS, Saelens BE, Schetzina KE, et al. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics. 2007;120(Suppl. 4):S254–S288
  21. Treadwell JR, Sun F, Scholles K. Systematic review and meta-analysis of bariatric surgery for pediatric obesity. Annals of Surgery. 2008;248:763–776
  22. Warman JL. The application of laparoscopic bariatric surgery for treatment of severe obesity in adolescents using a multidisciplinary adolescent bariatric program. Critical Care Nursing Quarterly. 2005;28:276–287
  23. Wirth A, Kraus J. Long-term weight loss with sibutramine. Journal of the American Medical Association. 2001;286:1331–1339
  24. Wilfley, D. E., Crow, S. J., Hudson, J. I., Mitchell, J. E., Berkowitz, R. I., & Blakesley, V., et al. The Sibutramine Binge Eating Disorder Research Group. (2008). Efficacy of sibutramine for the treatment of binge eating disorder: A randomized multicenter placebo-controlled double-blind study. American Journal of Psychiatry, 165, 51–58.

 Conflict of interest: None to report.

PII: S0891-5245(09)00109-6

doi: 10.1016/j.pedhc.2009.04.005

Journal of Pediatric Health Care
Volume 23, Issue 4 , Pages 206-212 , July 2009

Article Tools